Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cidara Thera (CDTX)

Cidara Thera (CDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 163,622
  • Shares Outstanding, K 7,047
  • Annual Sales, $ 63,910 K
  • Annual Income, $ -22,930 K
  • EBIT $ -121 M
  • EBITDA $ -121 M
  • 60-Month Beta 1.13
  • Price/Sales 2.48
  • Price/Cash Flow N/A
  • Price/Book 1.37

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 105.98%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -5.28
  • Number of Estimates 1
  • High Estimate -5.28
  • Low Estimate -5.28
  • Prior Year -0.80
  • Growth Rate Est. (year over year) -560.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.17 +35.26%
on 11/21/24
24.99 -7.08%
on 12/17/24
+8.10 (+53.57%)
since 11/20/24
3-Month
10.14 +128.99%
on 10/15/24
24.99 -7.08%
on 12/17/24
+11.95 (+106.03%)
since 09/20/24
52-Week
10.00 +132.11%
on 04/23/24
24.99 -7.08%
on 12/17/24
+8.22 (+54.80%)
since 12/20/23

Most Recent Stories

More News
Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

CDTX : 23.22 (+3.15%)
Cidara Therapeutics Announces $105 Million Securities Purchase Agreement to Advance Drug Development

Cidara Therapeutics announced a $105 million private placement to fund research and development of its immunotherapy candidates.Quiver AI SummaryCidara Therapeutics, Inc. has announced a securities purchase...

CDTX : 23.22 (+3.15%)
Cidara Therapeutics Announces $105 Million Private Placement

CDTX : 23.22 (+3.15%)
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference

CDTX : 23.22 (+3.15%)
Cidara Therapeutics: Q3 Earnings Snapshot

Cidara Therapeutics: Q3 Earnings Snapshot

CDTX : 23.22 (+3.15%)
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

CDTX : 23.22 (+3.15%)
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences

CDTX : 23.22 (+3.15%)
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024

CDTX : 23.22 (+3.15%)
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

CDTX : 23.22 (+3.15%)
Cidara Therapeutics: Q2 Earnings Snapshot

Cidara Therapeutics: Q2 Earnings Snapshot

CDTX : 23.22 (+3.15%)

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

3rd Resistance Point 27.21
2nd Resistance Point 25.61
1st Resistance Point 24.41
Last Price 23.22
1st Support Level 21.61
2nd Support Level 20.01
3rd Support Level 18.81

See More

52-Week High 24.99
Last Price 23.22
Fibonacci 61.8% 19.27
Fibonacci 50% 17.50
Fibonacci 38.2% 15.73
52-Week Low 10.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar